CAN-FITE BIOPHARMA LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.7 ILa | +23.33% |
|
+27.59% | +42.31% |
| Jun. 10 | Can-Fite Biopharma Ltd. Receives IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study | CI |
| Jun. 06 | Transcript : Can-Fite BioPharma Ltd. - Special Call |
| Sales 2024 * | 900K 335M | Sales 2025 * | 900K 335M | Capitalization | 14.91M 5.54B |
|---|---|---|---|---|---|
| Net income 2024 * | -7M -2.6B | Net income 2025 * | -8M -2.98B | EV / Sales 2024 * | 16.6 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 16.6 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 8 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.97% |
More Fundamentals
* Assessed data
More news
Latest transcript on Can-Fite BioPharma Ltd.
More press releases
| 1 day | +23.33% | ||
| 1 week | +27.59% | ||
| Current month | +37.04% | ||
| 1 month | +37.04% | ||
| 3 months | +37.04% | ||
| 6 months | +42.31% | ||
| Current year | +42.31% |
1 week
2.90
3.80
1 month
2.603.80
Current year
2.503.80
1 year
2.504.10
3 years
2.1028.50
5 years
2.1052.80
10 years
2.101 163.00
| Managers | Title | Age | Since |
|---|---|---|---|
Motti Farbstein
CEO | Chief Executive Officer | 59 | 03-07-31 |
Pnina Fishman
FOU | Founder | 74 | 94-09-10 |
Ilan Cohn
FOU | Founder | 68 | 94-09-10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Abraham Sartani
BRD | Director/Board Member | 76 | 00-12-31 |
Ilan Cohn
FOU | Founder | 68 | 94-09-10 |
Pnina Fishman
FOU | Founder | 74 | 94-09-10 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-13 | 3.7 | +23.33% | 49,322,760 |
| 24-06-10 | 3 | 0.00% | 14,801,560 |
| 24-06-09 | 3 | +3.45% | 5,072,483 |
| 24-06-06 | 2.9 | -3.33% | 14,729,160 |
Delayed Quote TEL AVIV STOCK EXCHANGE, June 13, 2024 at 10:24 am EDT
More quotes
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Sector
Pharmaceuticals
Calendar
2024-06-26
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.037
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +42.31% | 14.9M | |
| +0.85% | 92.38B | |
| -3.03% | 37.9B | |
| -10.46% | 33.73B | |
| +74.71% | 27.98B | |
| -13.39% | 15.86B | |
| -1.08% | 13.97B | |
| -11.15% | 11.67B | |
| +169.04% | 10.17B | |
| -50.19% | 10.04B |
- Stock Market
- Equities
- CANF Stock
